Iloprost infusion does not reduce oxidative stress in systemic sclerosis

Area of Science:

• Rheumatology
• Vascular Biology
• Oxidative Stress Research

Background:

• Systemic sclerosis (SSc) is a connective tissue disease characterized by complex pathogenetic mechanisms involving oxidative stress.
• Iloprost, a prostacyclin analogue, is clinically used for severe Raynaud's phenomenon and ischemic ulcers in SSc patients.
• Iloprost is known to attenuate oxidative damage from ischemia-reperfusion in experimental settings.

Purpose of the Study:

• To evaluate the effect of iloprost on the oxidative status of SSc patients.
• To measure urinary levels of 8-isoprostaglandin-F(2alpha) as a biomarker of oxidative stress.

Main Methods:

• A study involving ten patients diagnosed with systemic sclerosis.
• Cyclical treatment with iloprost was administered to the patients.
• Urinary 8-isoprostaglandin-F(2alpha) levels were measured before, during, and after iloprost treatment, with follow-ups at 3, 15, and 30 days.
• Comparison of levels between SSc patients and healthy subjects.

Main Results:

• Systemic sclerosis patients treated with iloprost exhibited higher urinary 8-isoprostaglandin-F(2alpha) levels compared to healthy individuals.
• Urinary 8-isoprostaglandin-F(2alpha) levels did not decrease immediately after iloprost infusion.
• Levels remained elevated at 3, 15, and 30 days post-administration, suggesting no reduction in oxidative status.

Conclusions:

• In vivo, the potent vasodilator effect of iloprost infusion did not mitigate the oxidative status in systemic sclerosis patients.
• Contrary to experimental findings, iloprost did not reduce oxidative stress markers in this patient cohort.
• Further research is needed to understand the discrepancy between experimental and clinical observations regarding iloprost and oxidative stress in SSc.